Open AccessClinical and Genomic Characterization of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Infections in mRNA Vaccinated Health Care Personnel in New York City
Author(s) -
Elizabeth Robilotti,
Karissa Whiting,
Anabella Lucca Bianchi,
Chester Poon,
Rebecca Guest,
Tracy McMillen,
Krupa Jani,
Alexander Solovyov,
Suzanne Kelson,
Kevin P. Browne,
Scott Freeswick,
Tobias M. Hohl,
Deborah Korenstein,
Denis Ruchnewitz,
Michael Lässig,
Marta Łuksza,
Benjamin Greenbaum,
Venkatraman Seshan,
N. Esther Babady,
Mini Kamboj
Publication year - 2021
Publication title -
clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciab886
Subject(s) - medicine , vaccination , virology , covid-19 , cohort , delta , infectious disease (medical specialty) , disease , engineering , aerospace engineering
Vaccine-induced clinical protection against severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) variants is an evolving target. There are limited genomic level data on SARS CoV-2 breakthrough infections and vaccine effectiveness (VE) since the global spread of the B.1.617.2 (Delta) variant.